Intent to Apply (ITA)
A total of 17 eligible ITA forms were received. A breakdown of eligible ITA forms by disease, intervention and development stage is shown below:

**Disease**
- Leishmaniasis, 9
- Schistosomiasis, 4
- Chagas disease, 3
- Human African Trypanosomiasis, 1
- Soil-Transmitted Helminths, 2

**Intervention**
- Diagnostics, 5
- Drug, 8
- Vaccine, 4

**Development Stage**
- Pre-clinical, 12
- Clinical, 7

*One or more ITA included multiple diseases, interventions and/or development stages in the scope.*
A total of 15 eligible proposals were received. A breakdown of eligible proposals by disease, development stage and intervention is shown below:

*One or more proposal included multiple diseases, interventions and/or development stages in the scope.*
**Award Notification**

The following three projects were awarded funding.

<table>
<thead>
<tr>
<th>Project Title</th>
<th>Collaboration Partners</th>
<th>Disease</th>
<th>Intervention</th>
<th>Development Stage</th>
<th>Total Amount</th>
</tr>
</thead>
</table>
| Development of a Sensitive and Specific Point-Of-Care Diagnostics for Asian Zoonotic Schistosomiasis | 1. Obihiro University of Agriculture and Veterinary Medicine, Japan  
2. The University of Tokyo, Japan  
3. University of the Philippines- Manila, Philippines  
4. InBios International, Inc. | Schistosomiasis | Diagnostics | Pre-Clinical | ¥77,903,630 |
| Development and registration of a new pediatric praziquantel formulation for the treatment of schistosomiasis | 1. Stichting Top Institute Pharm  
2. Merck KGaA  
3. Astellas Pharma Inc.  
4. Swiss Tropical and Public Health Institute  
5. Fundação Oswaldo Cruz trough its Technical-Scientific Unit Institute of Technology in Drugs Farmanguinhos  
6. Simcyp Limited | Schistosomiasis | Drug | Clinical | ¥485,651,320 |
| Lead Optimization of the aminopyrazole series for Visceral Leishmaniasis       | 1. DNDi – Drugs for Neglected Diseases initiative  
2. Takeda Pharmaceutical Company Limited | Leishmaniasis | Drug | Pre-Clinical | ¥402,255,299 |